Analysts are intrested in these 5 stocks: ( (FCX) ), ( (LUV) ) and ( (HIMS) ). Here is a breakdown of their recent ratings and the rationale behind them.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Freeport-McMoRan is back under the microscope after Morgan Stanley’s Carlos De Alba cut his rating to Hold, even as he lifted the year-end 2026 target price to $66 per share. He argues that slower production ramp-up and higher temporary costs at the Grasberg Block Cave mine in Indonesia will weigh on performance, leaving limited upside despite the stock’s recent selloff.
On De Alba’s 2027 estimates, Freeport trades at 7.4 times EV/EBITDA and 14.8 times earnings, slightly above its five-year averages, with free cash flow of 6.3%. The new target assumes an 8.1 times EV/EBITDA multiple, one standard deviation above history, reflecting confidence in long-term copper fundamentals but skepticism that the stock can outperform peers near term unless Indonesia ramps faster or commodity prices surprise to the upside.
Southwest Airlines is drawing fresh attention after HSBC’s Achal Kumar upgraded the stock to Hold, raising the target price sharply to $36.10 from $24.40. The call comes despite a slight first-quarter earnings miss tied to higher fuel costs, as new revenue initiatives drove an 11.2% jump in unit revenue and helped expand operating margins into positive territory.
Kumar notes that Southwest’s valuation still looks appealing, with the airline trading at about 5.2 times forward EV/EBITDA, a discount to its post-pandemic average while peers command healthy premiums. The firm sees strong revenue momentum from fare upgrades, healthy demand, and potential benefits from low-cost rival Spirit’s troubles, though investors should brace for volatility given fuel price uncertainty and an earnings outlook that hinges on cost discipline.
Hims & Hers Health has become a high-conviction idea for J.P. Morgan’s Cory Carpenter, who initiated coverage with a Buy rating and a $35 December 2026 price target. The direct-to-consumer healthcare platform, with 2.5 million subscribers, is riding a wave of demand in weight loss drugs, women’s health, and sexual wellness, even as skeptics keep it one of the most shorted names in the S&P 400.
Carpenter believes the recent partnership with Novo Nordisk, which could support 100,000-plus monthly Wegovy prescriptions, transforms Hims’ GLP-1 weight loss business and eases regulatory fears. Combined with potential upside from peptide legalization, new specialties, and additional branded deals, he values the stock at 22 times expected 2027 EBITDA, arguing that its growth profile, vertical integration, and brand strength warrant a premium to typical digital health and subscription peers.